Clinical Trial Update: Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH) [Phase 2]

View source ↗

Summary

Phase 2 pediatric trial of Elafibranor in children 8-17 with nonalcoholic steatohepatitis was terminated; results posted but details not provided here.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Steatohepatitis

Drugs mentioned

• Elafibranor

Snippet

Sponsor: Genfit | Conditions: Non Alcoholic Steatohepatitis | Phase 2 | Status: TERMINATED | Results posted: 2021-10-28